Genetic and Immune Factors in Squaring the Room: Sacituzumab plus Radiation for Bladder Cancer
Official title: Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11416566 · Data updated 2026-11-12
A study aims to understand why combining sacituzumab with radiation helps some bladder cancer patients more than others, with the goal of making bladder-sparing therapy more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 14, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $157,166 |
| NIH project number | 5U54CA274513-05 |
| Project ID | NIH-11416566 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with muscle-invasive bladder cancer eligible for bladder-sparing approaches involving sacituzumab or chemotherapy plus radiation.
✕Less likely to help
Patients whose tumors do not show the genetic or immune characteristics associated with response may not benefit from the proposed combination strategies.
What this research studies
This project focuses on muscle-invasive bladder cancer and explores how genetic and immune factors affect how well the combination of sacituzumab and radiation works. Researchers will study tumor genetics and the surrounding immune environment to identify why some tumors respond and others resist therapy. The work builds on preliminary data to uncover mechanisms of efficacy and resistance, with the ultimate aim of guiding better treatment options that preserve the bladder. The study uses a translational approach, bridging basic biology and potential clinical applications to improve patient outcomes.
Why it matters
Potential benefit: If successful, the findings could lead to more effective, bladder-sparing treatments for bladder cancer patients.
How similar studies have gone: Preliminary data suggest genetic and immune factors influence response to radiation and antibody-drug conjugates in bladder cancer, but this specific combination needs confirmation.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Chan, Timothy an-Thy — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chan, Timothy an-Thy
Related research
Other NIH-funded projects on the same topics.
-
Targeted Internal Radiation and Immune Therapy for Non-Muscle-Invasive Bladder Cancer
Aims to help people with early bladder cancer that doesn’t respond to current therapy by using a novel intravesical treatment that combines targeted radiation, immune checkpoint inhibitors, and oncolytic virus to trigger a strong anti-cancer response.
-
How genetics and the immune system affect sacituzumab plus radiation for bladder cancer
This work looks at whether adding the antibody-drug sacituzumab to radiation helps people with muscle-invasive bladder cancer and which genetic or immune factors change that response.
-
Understanding how genetic and immune factors affect bladder cancer treatment with sacituzumab and radiation.
This study is looking at how your genes and immune system affect how well bladder cancer patients respond to a special treatment that combines a drug called sacituzumab with radiation, so we can find out why some people do better than others and help create better treatments for everyone.
-
Protecting small blood vessels from radiation by boosting mitochondrial health
It aims to prevent radiation-related damage to tiny blood vessels and reduce later thinking and memory problems in people who get radiation therapy by protecting cell mitochondria.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.